RxDoctor Payments Data

Taylor Kane, PA

Physician Assistant · Sioux Falls, SDNPI 1942938725

Payments from drug & device makers

$1,592in general payments, 2019–2025

Across 69 payments — averaging $23.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$517
  • Otsuka America Pharmaceutical, Inc.$232
  • Johnson & Johnson$227
  • Axsome Therapeutics, Inc.$125
  • Livanova USA, Inc.$117
  • Neurocrine Biosciences, Inc.$97
  • plus $276 from 8 others

What the payments were for

  • Food & beverage$1,592100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,592 in reported general payments places this provider in the 85th percentile of 548 physician assistant providers in South Dakota.

See all physician assistant providers in South Dakota

Medicare billing

Part B allowed, 2024
$85,430
Medicare patients
54
Services billed
994

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate12$109,393
VraylarCariprazine Hcl11$24,513
LybalviOlanzapine/Samidorphan Malate12$19,661
TrintellixVortioxetine Hydrobromide11$7,568
Aripiprazole53$5,707
Ziprasidone Hcl23$3,479
Quetiapine Fumarate138$2,782
Clonazepam167$2,449
Hydroxyzine Hcl90$2,277
Venlafaxine Hcl ErVenlafaxine Hcl35$1,865
Duloxetine Hcl87$1,826
Gabapentin80$1,258
Bupropion XlBupropion Hcl58$924
Mirtazapine59$829
Eszopiclone37$813

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$97$109,39312 claims
AbbVieVraylar$517$24,51311 claims
Alkermes, Inc.Lybalvi$65$19,66112 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$12$7,56811 claims
Almatica Pharma LLCSertraline Hcl$20$734125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 548 physician assistant providers in South Dakota.

Other physician assistant in Sioux Falls

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →